Important update: Healthcare facilities
CDC has updated select ways to operate healthcare systems effectively in response to COVID-19 vaccination. Learn more
To maximize protection from the Delta variant and prevent possibly spreading it to others, get vaccinated as soon as you can and wear a mask indoors in public if you are in an area of substantial or high transmission.
UPDATE
Given new evidence on the B.1.617.2 (Delta) variant, CDC has updated the guidance for fully vaccinated people. CDC recommends universal indoor masking for all teachers, staff, students, and visitors to K-12 schools, regardless of vaccination status. Children should return to full-time in-person learning in the fall with layered prevention strategies in place.

SARS-CoV-2 Variant Classifications and Definitions

SARS-CoV-2 Variant Classifications and Definitions

Key Points

email_03Get Variant Classification and Definition Updates

To receive email updates when a variant classification or definition changes, enter your email address:

  • Genetic variants of SARS-CoV-2 have been emerging and circulating around the world throughout the COVID-19 pandemic.
  • Viral mutations and variants in the United States are routinely monitored through sequence-based surveillance, laboratory studies, and epidemiological investigations.
  • The US government SARS-CoV-2 Interagency Group (SIG) developed a Variant Classification scheme that defines three classes of SARS-CoV-2 variants:
  • The Alpha (B.1.1.7), Beta (B.1.351, B.1.351.2, B.1.351.3), Delta (B.1.617.2, AY.1, AY.2, AY.3), and Gamma (P.1, P.1.1, P.1.2) variants circulating in the United States are classified as variants of concern.
  • To date, no variants of high consequence have been identified in the United States.
  • Due to the increasing number of sublineages that are associated with Alpha, Delta and Gamma, unless otherwise specified, CDC will refer to the lineages collectively as Q sublineages (Alpha), AY sublineages (Delta) and P.1 sublineages (Gamma).
  • Laboratory studies suggest bamlanivimab and etesevimab may be less effective for treating cases of COVID-19 caused by variants with certain substitutions or combinations of substitutions in the spike protein.
  • Importantly, the vast majority of Delta variant lineages are sensitive to the combination of bamlanivimab and etesevimab.
  • Clinicians seeking advice on the use of monoclonal antibody products authorized for emergency use in the United States for the treatment and prevention of SARS-CoV-2 should consult the NIH COVID-19 Treatment Guidelinesexternal icon.
  • Vaccines authorized for use in the United States are effective against these variants and effective therapeutics are available. CDC continues to monitor all variants circulating within the United States.
email_03Get Variant Classification and Definition Updates

To receive email updates when a variant classification or definition changes, enter your email address:

Delta Variant

The Delta variant causes more infections and spreads faster than earlier forms of the virus that causes COVID-19. It might cause more severe illness than previous strains in unvaccinated people.

  • Vaccines continue to reduce a person’s risk of contracting the virus that cause COVID-19, including this variant.
  • Vaccines continue to be highly effective at preventing hospitalization and death, including against this variant.
  • Fully vaccinated people with breakthrough infections from this variant appear to be infectious for a shorter period.
  • Get vaccinated and wear masks indoors in public spaces to reduce the spread of this variant.

About the Delta VariantVariants in the US

 The virus that causes COVID-19 is constantly changing. A variant has one or more mutations that differentiate it from other variants in circulation. As expected, multiple variants of SARS-CoV-2 have been documented in the United States and globally throughout this pandemic. To inform local outbreak investigations and understand national trends, scientists compare genetic differences between viruses to identify variants and how they are related to each other.

Variant classifications

The US Department of Health and Human Services (HHS) established a SARS-CoV-2 Interagency Group (SIG) to improve coordination among the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), Food and Drug Administration (FDA), Biomedical Advanced Research and Development Authority (BARDA), and Department of Defense (DoD). This interagency group is focused on the rapid characterization of emerging variants and actively monitors their potential impact on critical SARS-CoV-2 countermeasures, including vaccines, therapeutics, and diagnostics.

Notes: Each classification of variant includes the possible attributes of lower classes (e.g., VOC includes the possible attributes of VOI); variant status might escalate or deescalate based on emerging scientific evidence. This page will be updated as needed to show the variants that belong to each class. The World Health Organizationexternal icon (WHO) also classifies variant viruses as Variants of Concern and Variants of Interest; US classifications may differ from those of WHO because the importance of variants may differ by location. To assist with public discussions of variants, WHO proposed using labels consisting of the Greek Alphabet, e.g., Alpha, Beta, Gamma, as a practical way to discuss variants by non-scientific audiences. The labels assigned to each variant are provided in the tables below.

Variant of Interest

A variant with specific genetic markers that have been associated with changes to receptor binding, reduced neutralization by antibodies generated against previous infection or vaccination, reduced efficacy of treatments, potential diagnostic impact, or predicted increase in transmissibility or disease severity.

Possible attributes of a variant of interest:

  • Specific genetic markers that are predicted to affect transmission, diagnostics, therapeutics, or immune escape.
  • Evidence that it is the cause of an increased proportion of cases or unique outbreak clusters.
  • Limited prevalence or expansion in the US or in other countries.

A variant of interest might require one or more appropriate public health actions, including enhanced sequence surveillance, enhanced laboratory characterization, or epidemiological investigations to assess how easily the virus spreads to others, the severity of disease, the efficacy of therapeutics and whether currently approved or authorized vaccines offer protection.

Current variants of interest in the United States that are being monitored and characterized are listed below. This will be updated when a new variant of interest is identified.

Selected Characteristics of SARS-CoV-2 Variants of Interest

WHO Label: Eta

Pango Lineage: B.1.525 (Pango lineageexternal icon)a

Spike Protein Substitutions: A67V, 69del, 70del, 144del, E484K, D614G, Q677H, F888L

Name (Nextstrainexternal icon)b: 20A/S:484K

First Identified: United Kingdom and Nigeria – December 2020

Attributes:

  • Potential reduction in neutralization by some Emergency Use Authorization (EUA) monoclonal antibody treatments 7, 14
  • Potential reduction in neutralization by convalescent and post-vaccination sera22

WHO Label: Iota

Pango Lineage: B.1.526 (Pango lineageexternal icon)a

Spike Protein Substitutions: L5F, (D80G*), T95I, (Y144-*), (F157S*), D253G, (L452R*), (S477N*), E484K, D614G, A701V, (T859N*), (D950H*), (Q957R*)

Name (Nextstrainexternal icon)b: 20C/S:484K

First Identified: United States (New York) – November 2020

BEI Reference Isolatec: NR-55359external icon

Attributes:

  • Reduced susceptibility to the combination of bamlanivimab and etesevimab monoclonal antibody treatment; however, the clinical implications of this are not known.7 Alternative monoclonal antibody treatments are available.14
  • Reduced neutralization by convalescent and post-vaccination sera22, 24

WHO Label: Kappa

Pango Lineage: B.1.617.1 (Pango lineageexternal icon)a

Spike Protein Substitutions: (T95I), G142D, E154K, L452R, E484Q, D614G, P681R, Q1071H

Name (Nextstrainexternal icon)b: 20A/S:154K

First Identified: India – December 2020

Attributes:

  • Potential reduction in neutralization by some EUA monoclonal antibody treatments7, 14
  • Potential reduction in neutralization by post-vaccination sera26

WHO Label: None

Pango Lineage: B.1.617.3 (Pango lineageexternal icon)a

Spike Protein Substitutions: T19R, G142D, L452R, E484Q, D614G, P681R, D950N

Name (Nextstrainexternal icon)b: 20A

First Identified: India – October 2020

Attributes:

  • Potential reduction in neutralization by some EUA monoclonal antibody treatments7, 14
  • Potential reduction in neutralization by post-vaccination sera26

Variant of Concern

A variant for which there is evidence of an increase in transmissibility, more severe disease (e.g., increased hospitalizations or deaths), significant reduction in neutralization by antibodies generated during previous infection or vaccination, reduced effectiveness of treatments or vaccines, or diagnostic detection failures.

Possible attributes of a variant of concern:

In addition to the possible attributes of a variant of interest

  • Evidence of impact on diagnostics, treatments, or vaccines
    • Widespread interference with diagnostic test targets
    • Evidence of substantially decreased susceptibility to one or more class of therapies
    • Evidence of significant decreased neutralization by antibodies generated during previous infection or vaccination
    • Evidence of reduced vaccine-induced protection from severe disease
  • Evidence of increased transmissibility
  • Evidence of increased disease severity

Variants of concern might require one or more appropriate public health actions, such as notification to WHO under the International Health Regulations, reporting to CDC, local or regional efforts to control spread, increased testing, or research to determine the effectiveness of vaccines and treatments against the variant. Based on the characteristics of the variant, additional considerations may include the development of new diagnostics or the modification of vaccines or treatments.

Current variants of concern in the United States that are being closely monitored and characterized are listed below. This table will be updated when a new variant of concern is identified.

Selected Characteristics of SARS-CoV-2 Variants of Concern

WHO Label: Alpha

Pango Lineage: B.1.1.7 and Q sublineages (Pango lineageexternal icon)a

Spike Protein Substitutions: 69del, 70del, 144del, (E484K*), (S494P*), N501Y, A570D, D614G, P681H, T716I, S982A, D1118H (K1191N*)

Name (Nextstrainexternal icon)b: 20I/501Y.V1

First Identified: United Kingdom

BEI Reference Isolatec: NR-54000external icon

Attributes:

  • ~50% increased transmission5
  • Potential increased severity based on hospitalizations and case fatality rates6
  • No impact on susceptibility to EUA monoclonal antibody treatments7,14
  • Minimal impact on neutralization by convalescent and post-vaccination sera8-13,19

WHO Label: Beta

Pango Lineage(s): B.1.351 and sublineages, B.1.351.2, B.1.351.3 (Pango lineageexternal icon)a

Spike Protein Substitutions: D80A, D215G, 241del, 242del, 243del, K417N, E484K, N501Y, D614G, A701V

Name (Nextstrainexternal icon)b: 20H/501.V2

First Identified: South Africa

BEI Reference Isolatec: NR-55282external icon

Attributes:

  • ~50% increased transmission16
  • Significantly reduced susceptibility to the combination of bamlanivimab and etesevimab monoclonal antibody treatment,7 but other EUA monoclonal antibody treatments are available14
  • Reduced neutralization by convalescent and post-vaccination sera8,12,18,19,20

WHO Label:  Delta

Pango Lineage: B.1.617.2 and all AY sublineages (Pango lineageexternal icon)a

Spike Protein Substitutions: T19R, (V70F*), T95I, G142D, E156-, F157-, R158G, (A222V*), (W258L*), (K417N*), L452R, T478K, D614G, P681R, D950N

Name (Nextstrainexternal icon)b: 21A/S:478K

First Identified: India

Attributes:

  • Increased transmissibility29
  • Potential reduction in neutralization by some EUA monoclonal antibody treatments7, 14
  • Potential reduction in neutralization by post-vaccination sera21

WHO Label: Gamma

Pango Lineage(s): P.1 and P.1 sublineages (Pango lineage)a

Spike Protein Substitutions: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I

Name (Nextstrainexternal icon)b: 20J/501Y.V3

First Identified: Japan/Brazil

BEI Reference Isolatec: NR-54982external icon

Attributes:

  • Significantly reduced susceptibility to the combination of bamlanivimab and etesevimab monoclonal antibody treatment,7 but other EUA monoclonal antibody treatments are available14
  • Reduced neutralization by convalescent and post-vaccination sera15

Variant of High Consequence

A variant of high consequence has clear evidence that prevention measures or medical countermeasures (MCMs) have significantly reduced effectiveness relative to previously circulating variants.

Possible attributes of a variant of high consequence:

In addition to the possible attributes of a variant of concern

  • Impact on Medical Countermeasures (MCM)
    • Demonstrated failure of diagnostic test targets
    • Evidence to suggest a significant reduction in vaccine effectiveness, a disproportionately high number of vaccine breakthrough cases, or very low vaccine-induced protection against severe disease
    • Significantly reduced susceptibility to multiple Emergency Use Authorization (EUA) or approved therapeutics
    • More severe clinical disease and increased hospitalizations

A variant of high consequence would require notification to WHO under the International Health Regulations, reporting to CDC, an announcement of strategies to prevent or contain transmission, and recommendations to update treatments and vaccines.

Currently, there are no SARS-CoV-2 variants that rise to the level of high consequence.

Substitutions of Concern for SARS-CoV-2 Monoclonal Antibody Therapies

In the United States, there are three anti-SARS-CoV-2 monoclonal antibody treatments with FDA Emergency Use Authorization (EUA) for the treatment of COVID-19: bamlanivimab plus etesevimabexternal icon, casirivimab plus imdevimab,external icon, and sotrovimabexternal icon.

CDC’s national genomic surveillance program identifies new and emerging SARS-CoV-2 variants to determine implications for COVID-19 diagnostics, treatments, or vaccines approved or authorized for use in the United States. Sequences with similar genetic changes are grouped into lineages, and multiple lineages can have the same substitutions. For example, the E484K substitution is found in lineages B.1.351, P.1, B.1.526, and many others. Genomic surveillance efforts provide the capability to detect viruses that have reduced susceptibility to treatments more quickly.

Reduced susceptibility of SARS-CoV-2 to sotrovimabexternal icon or the combination of casirivimab and imdevimabexternal icon has not been reported. In laboratory studies, SARS-CoV-2 variants that contain certain substitutions in the spike protein have reduced susceptibility to the combination of bamlanivimab and etesevimabexternal icon. Clinicians seeking advice on the use of monoclonal antibody products authorized for emergency use in the United States for the treatment and prevention of SARS-CoV-2 should consult the NIH COVID-19 Treatment Guidelinesexternal icon.

Given the predominance of the Delta variant in the United States, it is important to note that the vast majority of Delta variant lineages are sensitive to the combination of bamlanivimab and etesevimab. Although Delta variants contain the L452R substitution, the combination of the L452R and T478K substitutions found in most Delta variants results in no change in the susceptibility to the combination of bamlanivimab and etesevimab, as noted in the FDA Fact Sheet for Health Care Providersexternal icon.

The proportion data below show the national and regional unweighted proportions of SARS-CoV-2 that contain the following individual or combinations of spike protein substitutions that reduce susceptibility to the combination of bamlanivimab and etesevimab that are listed in the FDA Fact Sheet for Health Care Providers for EUA of Bamlanivimab and Etesevimabexternal icon. As new data become available, additional substitutions may be added below. The national and regional proportions provided below will be updated weekly.

  • L452R
  • E484K
  • L452R and E484Q
  • K417N, E484K, and N501Y
  • K417T, E484K, and N501Y
  • K417N, L452R, and T478K
  • R346K, E484K, and N501Y

Resources

Monoclonal Antibody COVID-19 Infusionexternal icon

Statement on Anti-SARS-CoV-2 Monoclonal Antibodies EUA | COVID-19 Treatment Guidelines (nih.gov)external icon

Unweighted Proportions of SARS-CoV-2 Substitutions of Therapeutic Concern

L452R Spike Protein Substitution
National Proportiona: 94.9%

Regional Proportionsb

Region 1
98.9%
Region 2
95.4%
Region 3
98.7%
Region 4
97.1%
Region 5
91.7%
Region 6
95.8%
Region 7
96.4%
Region 8
97.8%
Region 9
91.7%
Region 10
95.9%
Common Pango Lineages with Spike Protein Substitutionsc
B.1.617.2 (Delta)
AY.4 (Delta)
AY.3 (Delta)
AY.12 (Delta)
AY.3.1 (Delta)
AY.14 (Delta)
AY.20 (Delta)
AY.25 (Delta)
E484K Spike Protein Substitution
National Proportiona: 0.3%

Regional Proportionsb

Region 1
0.5%
Region 2
0.3%
Region 3
0.2%
Region 4
0.2%
Region 5
0.2%
Region 6
0.2%
Region 7
0.0%
Region 8
0.0%
Region 9
0.2%
Region 10
0.4%
Common Pango Lineages with Spike Protein Substitutionsc
B.1.621
P.1 (Gamma)
B.1.621.1
P.1.7 (Gamma)
P.1.4 (Gamma)
P.1.10 (Gamma)
B.1.617.2 (Delta)
B.1.626
B.1.632

K417N, E484K, N501Y Spike Protein Substitution
National Proportiona<0.1%

Regional Proportionsb

Region 1
0.0%
Region 2
0.1%
Region 3
0.0%
Region 4
0.0%
Region 5
0.0%
Region 6
0.0%
Region 7
0.0%
Region 8
0.0%
Region 9
0.0%
Region 10
0.0%
Common Pango Lineages with Spike Protein Substitutionsc
B.1.621

K417T, E484K, N501Y Spike Protein Substitution
National Proportiona: 0.1%

Regional Proportionsb

Region 1
0.1%
Region 2
0.1%
Region 3
0.1%
Region 4
0.1%
Region 5
0.1%
Region 6
0.2%
Region 7
0.0%
Region 8
0.0%
Region 9
0.1%
Region 10
0.1%
Common Pango Lineages with Spike Protein Substitutionsc
P.1 (Gamma)
P.1.10 (Gamma)
P.1.2 (Gamma)
P.1.4 (Gamma)
P.1.7 (Gamma)

L452R, E484Q Spike Protein Substitution
National Proportiona: 0.2%

Regional Proportionsb

Region 1
0.3%
Region 2
0.2%
Region 3
0.1%
Region 4
0.0%
Region 5
0.0%
Region 6
0.5%
Region 7
0.0%
Region 8
0.2%
Region 9
0.2%
Region 10
0.1%
Common Pango Lineages with Spike Protein Substitutionsc
B.1.617.2 (Delta)
AY.4 (Delta)
AY.7.2

K417N, L452R, T478K Spike Protein Substitution
National Proportiona: 0.4%

Regional Proportionsb

Region 1
0.1%
Region 2
0.5%
Region 3
0.1%
Region 4
0.1%
Region 5
0.0%
Region 6
0.1%
Region 7
0.0%
Region 8
0.2%
Region 9
1.1%
Region 10
0.3%
Common Pango Lineages with Spike Protein Substitutionsc
AY.2 (Delta)
AY.1 (Delta)
B.1.617.2 (Delta)
AY.4 (Delta)
AY.25 (Delta)

R346K, E484K, N501Y Spike Protein Substitution
National Proportiona: 0.1%

Regional Proportionsb

Region 1
0.3%
Region 2
0.2%
Region 3
0.1%
Region 4
0.1%
Region 5
0.1%
Region 6
0.1%
Region 7
0.0%
Region 8
0.0%
Region 9
0.0%
Region 10
0.2%
Common Pango Lineages with Spike Protein Substitutionsc
B.1.621
B.1.621.1

References